Bern-based machineMD attracted a strategic investment from Topcon Healthcare, Inc., a global leader in robotic diagnostics and digital solutions. Topcon Healthcare has joined machineMD’s pre-Series A funding round. This collaboration will integrate machineMD’s objective functional neurodiagnostics with Topcon’s Harmony digital health information platform, fostering earlier detection of neurological diseases within a connected care ecosystem.
Founded with a vision to enable faster, more accurate, and earlier diagnoses of neurological disorders, machineMD is pioneering oculometric analysis to assess brain function with precision. By leveraging neurodiagnostic expertise, the company is developing solutions that support individuals affected by conditions such as Multiple Sclerosis and Parkinson’s Disease.
Topcon Healthcare is leading machineMD’s pre-Series A round which has a target size of CHF 5 to 7 million. “Existing investors will also participate, we would like to cover the remaining 1-3M with new investors”, explains Dominic Senn, CEO and Co-founder of machineMD.
“Topcon Healthcare and machineMD share a bold ambition to shape the future of neurodiagnostics—making it more accessible, scalable, and data-driven,” said Dominic Senn. “With the backing of forward-thinking partners like Topcon Healthcare and our expanding network of clinical experts, we are accelerating our journey to establishing neurodiagnostics as the standard of care—ultimately improving millions of lives.
Topcon Healthcare’s pioneering initiative, Healthcare from the Eye, utilizes ocular data to identify ocular, systemic, or neurological disease in a coordinated care system that includes eyecare providers, primary care providers, and specialty care providers using secure and responsible technology. Through this partnership, machineMD’s neurodiagnostic capabilities will be integrated into Topcon Healthcare’s multimodal retinal imaging technologies, unlocking faster, cost-effective pathways for neurological disease detection and management.
Scaling commercialisation
machineMD’s flagship product, neos, leverages VR technology and gamified visual stimuli to capture precise oculomotor and pupillometric data. Already in clinical use across Switzerland and the USA, neos is streamlining workflows, paving the way for scalable and reimbursable neurodiagnostics.
The machineMD team intends to use the proceeds from the round to scale commercialization in primary care and the US market, advance neos for screening in primary care and to conduct studies on certain patient populations (MS, Parkinson’s, Alzheimer’s) and validate neos for screening in primary care.
Extensive collaboration with Topcon Healthcare
Ali Tafreshi, CEO and President of Topcon Healthcare, Inc., stated: “Our investment in machineMD reflects our commitment to expanding ocular-based diagnostics into the realm of neurological diseases. machineMD’s expertise and cutting-edge technology will enable more precise and earlier diagnoses, ultimately improving patient outcomes.”
By combining machineMD’s neurodiagnostic functional biomarkers with Topcon Healthcare’s multimodal retinal imaging-based biomarkers, the partnership will enhance clinical decision-making and patient management. Delivering these innovations through the Harmony cloud- based platform will create a seamless digital ecosystem for ocular and neurological diagnostics, empowering healthcare professionals with integrated data-driven insights.
Leave a Reply